European Medicines Agency Recommends Approval of Hexyon 6-in-1 Paediatric Vaccine

Lyon, France (ots/PRNewswire) -

Upon approval Hexyon will be the only fully liquid, ready-to-use
6-in-1 paediatric vaccine in Europe

Sanofi Pasteur MSD, the joint venture between MSD and Sanofi
Pasteur in Europe, announced today that their innovative 6-in-1
paediatric vaccine Hexyon has been recommended for marketing
authorisation by the European Medicines Agency's Committee for
Medicinal Products for Human Use (CHMP).

The new hexavalent vaccine, developed by Sanofi Pasteur, will be
commercialised in Europe under two brands names - in Western Europe*
by Sanofi Pasteur MSD under the brand name Hexyon and in Eastern
Europe by Sanofi Pasteur under the brand name Hexacima.

Hexyon is the only fully liquid, ready-to-use 6-in-1 vaccine to
protect infants against diphtheria, tetanus, pertussis (whooping
cough), Hepatitis B, poliomyelitis and invasive infections caused by
Haemophilus influenzae type b.

"We welcome the CHMP's positive recommendation," said Jean-Paul
Kress, President of Sanofi Pasteur MSD. "It validates the clinical
data supporting the vaccine's effective and safe use for infants.
Furthermore, its uniqueready-to-use formulation will provide
healthcare professionals with a simpler, more convenient vaccination
process."

Hexyon's formulation does not require reconstitution prior to
administration, so improving convenience. Hexyon will be indicated
for primary and booster vaccination of infants from six weeks to 24
months of age in accordance with official recommendations.

* France, Germany, UK, Spain, Italy, Belgium, Netherlands,
Austria, Portugal, Switzerland, Norway, Sweden, Denmark, Finland,
Ireland, Greece, Iceland, Luxembourg, Liechtenstein

About Sanofi Pasteur MSD http://www.spmsd.com

Sanofi Pasteur MSD is a joint venture between Sanofi Pasteur, the
vaccine division of Sanofi, and Merck, known as MSD outside the USA
and Canada. Combining innovation and expertise, Sanofi Pasteur MSD is
the only company in Europe dedicated exclusively to vaccines. Sanofi
Pasteur MSD is able to draw on the research expertise of Sanofi
Pasteur and Merck to focus on the development of new vaccines for
Europe to improve the acceptability, efficacy and tolerability of
vaccination.

ots Originaltext: Sanofi Pasteur MSD GmbH
Im Internet recherchierbar: http://www.presseportal.de

Contact:
For further information please contact: Caroline Ashe, Senior
Director External Communications Europe, Sanofi Pasteur MSD, Tel :
+33-4-37-28-4040, Mob :+33-6-33-46-1365, CAshe@spmsd.com